Diversity, urban space and the right to the provincial city

Using three vignettes of the same physical space this article contributes to understanding of how the right to the city is contested in provincial England in the early twenty-first century. Oral history and ethnographic material gathered in Peterborough between 2010 and 2012 are drawn on to shed new light on the politics of diversity and urban space. This highlights the multiple place attachments and trans-spatial practices of all residents, including the white ethnic majority, as well as contrasting forms of active intervention in space with their different temporalities and affective intensities. The article carries its own diversity politics, seeking to reduce the harm done by racism through challenging the normalisation of the idea of a local, indigenous population, left out by multiculturalism. It simultaneously raises critical questions about capitalist regeneration strategies in terms of their impact both on class inequality and on the environment

Antimalarial activity of cupredoxins: the interaction of Plasmodium Merozoite Surface Protein 119 (MSP119) and Rusticyanin

Background: The interaction of MSP119 with the cupredoxin azurin inhibits the growth of Plasmodium falciparum in red blood cells. Results: Rusticyanin forms a well-defined complex with MSP119 upon binding at the same surface area than inhibitory antibodies. Conclusion: Rusticyanin becomes an excellent therapeutic agent for malaria. Significance: Knowing the rusticyanin- MSP119 interface will allow the design of novel anti-malarial drugsJunta de Andalucía P08-CVI-3876, BIO198Ministerio de Economía y Competitividad SAF2011- 26611Fundación Séneca de la Región de Murcia 15354/PI/10Ministerio de Ciencia e Innovación BFU2010-19451Medical Research Council U117574558, U11753206

Justice and the racial dimensions of health inequalities:A view from COVID-19

In this paper, we take up the call to further examine structural injustice in health, and racial inequalities in particular. We examine the many facets of racism: structural, interpersonal and institutional as they appeared in the COVID‐19 pandemic in the UK, and emphasize the relevance of their systemic character. We suggest that such inequalities were entirely foreseeable, for their causal mechanisms are deeply ingrained in our social structures. It is by recognizing the conventional, un‐extraordinary nature of racism within social systems that we can begin to address socially mediated health inequalities

Fetomaternal outcome in patients with diabetes mellitus in pregnancy

Background: Diabetes mellitus (DM) is defined as increased blood glucose level due to defect in insulin secretion, insulin action or both. Undiagnosed or inadequately treated diabetes mellitus during pregnancy can lead to significant maternal and fetal complications. The study was conducted to review feto-maternal outcome in pregnancy with diabetes and to plan management of pregnancy with diabetes and to study the modalities for treatment of DM in pregnancy.Methods: A prospective case study was conducted from July 2015 to December 2018 at a tertiary care center. Study group used single step 75gm oral glucose tolerance test (OGTT) test recommended by WHO for GDM diagnosis.Results: GDM (85%) was more common than overt diabetes (15%) and in younger age group (53.75%) and Multiparous patients (18.2%). Most of patients required insulin (81.2%) for treatment of DM during pregnancy along with medical nutrition therapy and exercise. Most common association in this patient was hypertension (41%). Rate of caesarean section (60%) was more common. Average birth weight was of >3.5 kg, intrauterine death (4.2%), preterm delivery (14.2%) and admission to NICU were also common.Conclusions: There was significant fetomaternal morbidity in patients with diabetes mellitus. Early diagnosis and treatment reduces the fetomaternal outcome

Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach

Malaria is an infectious disease caused by parasites of the genus Plasmodium, which leads to approximately one million deaths per annum worldwide. Chemical validation of new antimalarial targets is urgently required in view of rising resistance to current drugs. One such putative target is the enzyme N-myristoyltransferase, which catalyses the attachment of the fatty acid myristate to protein substrates (N-myristoylation). Here, we report an integrated chemical biology approach to explore protein myristoylation in the major human parasite P. falciparum, combining chemical proteomic tools for identification of the myristoylated and glycosylphosphatidylinositol-anchored proteome with selective small-molecule N-myristoyltransferase inhibitors. We demonstrate that N-myristoyltransferase is an essential and chemically tractable target in malaria parasites both in vitro and in vivo, and show that selective inhibition of N-myristoylation leads to catastrophic and irreversible failure to assemble the inner membrane complex, a critical subcellular organelle in the parasite life cycle. Our studies provide the basis for the development of new antimalarials targeting N-myristoyltransferase

Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)

N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high affinity inhibitor of both Plasmodium falciparum and P. vivax NMT and displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a previously described series. Development, guided by targeting a ligand efficiency dependent lipophilicity (LELP) score of less than 10, yielded a 100-fold increase in enzyme affinity and a 100-fold drop in lipophilicity with the addition of only two heavy atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for further optimization

Stock Market Prediction and Analysis Using Naïve Bayes

The stock market is the most popular investing places for users. Because of its expected high profit. Recently forecasting stock market returns gaining more attention. The prediction of stock markets is regarded as a challenging task. Data analysis is the way of predicting future value. if future stocks prices will increase or decrease. The main objective of this paper is to predict future stock price using prediction concept. In that Parse Records then calculate predicted value and send to user. And automatically perform operations like purchase and sale shares using Automation concept. For that use Naïve Bayes Algorithm. There is Real time Access by Download log forms yahoo finance website and Store in dataset

The European Hematology Association Roadmap for European Hematology Research: a consensus document

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients

Tofidence Biosimilar: A Promising Frontier

Tofidence, a biosimilar of Actemra (Tocilizumab), has been approved for use in the United States, offering new hope for individuals suffering from autoimmune disorders. The significance of Tofidence in addressing autoimmune diseases including rheumatoid arthritis. Tofidence is seen as a positive step toward enhancing access to advanced therapies for chronic autoimmune disorders, benefiting both patients and healthcare systems. Biogen\u27s involvement in commercialization and licensing arrangements for Tofidence has been highlighted, further underlining the importance of biosimilars in expanding treatment options and improving affordability for patients with autoimmune diseases. Along with providing a review of regulations, this article also highlights the difficulties in developing biosimilars. The first biosimilar for the RA, the biosimilarity of bioequivalence and bioavailability research requirements are addressed by regulation. The successful adoption of biologics has the potential to reduce costs, which will benefit both patients and healthcare providers. We go over the available biologics, those that are being developed, and the difficulties that biosimilar producers are facing in this article. Introduction: Rheumatoid arthritis (RA) is an autoimmune illness that affects 0.5–1% of people worldwide. It is the second most frequent kind of arthritis, after osteoarthritis [1]. This translates to about 400,000 individuals in the United Kingdom and 78 million people worldwide. Nearly 30% of patients still have untreated disease despite the wide range of medications available; this means that 23–25 million people are searching for alternative therapies. acknowledge this, hence there\u27s a rivalry to take market share from biologics that are losing their Patents [2]. As the primary cause of work impairment, RA accounts for two-thirds of lost workdays yearly for its patients, costing the UK economy £1.8 billion in lost output [3]. Patients in the US are estimated to pay between $1300 and$3000 for every treatment, adding up to a total of $30,000 per year. The average yearly cost of RA treatment is significant. In the United Kingdom, the National Health Service (NHS) is anticipated to spend £560 million annually on RA [4]. A recent analysis estimates that the annual expenses of Medicare and privatised healthcare in the US will be$600 million and $306 million, respectively. Thus, RA indicates a substantial load on global healthcare systems [5]. Since pharmaceutical companies are aware of this, a race has arisen to capture market share from biologics that are no longer covered by patents. The number of potential biosimilars and biobetters for a variety of biologics available on the market

SaMD Synergy: Bridging Innovation and Regulation in the AI Healthcare Era

The emergence of Software as Medical Devices (SaMD) in modern healthcare signifies a paradigm shift, integrating software applications and algorithms into critical medical processes. SaMD, ranging from diagnostic tools to telemedicine platforms, enhances healthcare accessibility and efficiency, shaping personalized medicine and improving patient outcomes. This abstract delves into the regulatory landscape, emphasizing the complexities of SaMD compliance with stringent medical device regulations. The paper underscores the pivotal role of SaMD in reshaping healthcare, While SaMD streamlines healthcare processes and fosters collaboration, the paper highlights the pressing need for regulatory frameworks to navigate this transformative landscape. IMDRF in year 2013 formed the software as medical device working group to develop guidance for SaMD. Software as a medical device working group was chaired by FDA. After 2013 the guidelines for SaMD have evolved considering risk categorization, quality management system and clinical evaluation. The challenges faced by regulators in ensuring the safety and efficacy of AI-driven SaMD underline the critical importance of addressing these complexities for the future of medical practice and patient experiences. The IEC 62304 is the standard for the risk management specially for the medical devices with reference to ISO 14971 for Quality Management System. The various application of SaMD is in Mobile ECG Apps, MRI, Computer Aided Detection, Mammography Image Analysis Software etc. Future application of AI based SaMD is going to become an integral part of healthcare system